We’re working on a more direct way to get therapies from the nose to the brain.
Most therapies struggle to get past the blood-brain barrier, which limits how much actually reaches the central nervous system. Kurve is developing ViaNase™, an investigational intranasal technology that explores a more direct route from the nose to the brain.
ViaNase™ delivers medication nose-to-brain, a direct route past the blood-brain barrier that keeps most drugs out of the brain.
Whether you treat patients, care for someone, or want to work with us, start here.
See our clinical development, trials and peer-reviewed publications.
ViaNase™ is available only through clinical studies and FDA expanded access. Tell us who you are and we’ll guide you to the right route.
Read our latest news and press releases.
Chronic sinusitis affects 30 million patients in the U.S. alone.
Central Nervous System disorders are complex, debilitating diseases that affect countless patients across the world, yet there is no cure. It’s difficult to see people we love struggle so much, and it’s even more difficult to find treatment options that are simple, non-invasive, and effective. . . until now.
most-cited research in nose-to-brain delivery of molecules larger than 1 kilodalton
Kurve Therapeutics' nose-to-brain delivery platform is behind the two most-cited papers in the field.
ViaNase™ is available through Kurve’s clinical studies and FDA expanded access (compassionate use). Tell us who you are and we’ll guide you to the right route.
